Comprehensive bacterial composition for odor reduction

Abstract

Use of a composition comprising bacteria for odor reduction in the treatment of symptoms of tissue necrosis, wound secretions or putrid wounds or a disease selected from the group consisting of ozena, hyperhidrosis, osmidrosis, chronic urinary tract infections, chlamydial infections and halitosis; wherein the composition comprises the bacteria Lactobacillus acidophilus TYCA15, Lactobacillus salivarius, Bifidobacterium animalis, Bifidobacterium bifidum and Bifidobacterium longum in the ratio 1:1:1:1:1; and the composition totals 10 9 bacteria per gram of the composition.

Description

[0001] The invention relates to an odor-reducing composition comprising bacteria, the use of the composition, and a product containing the composition.

[0002] Unpleasant body odors pose a problem for those affected and their surroundings in many ways, especially for caregivers, family members, and everyone in the affected person's social circle. The odor emanating from the affected person often leads to social deprivation. Due to the diverse olfactory causes of odor-inducing bodily excretions and their breakdown products, conventionally used methods for odor reduction or control are difficult to implement.

[0003] Conventional methods for odor reduction in personal hygiene are based on disinfection, masking unpleasant odors with perfume-like substances, antibiotic effects, and detergents (surface-active agents). Such disinfecting, deodorizing, or odor-masking products are usually limited by their short duration of action, as a limited amount of product is countered by continuous odor formation. Consequently, these products must be reapplied constantly to remain effective. An excess of odor-causing substances creates an unpleasant mixture of odor-causing substances and deodorants. Skin irritation and unwanted allergic reactions are also common.Furthermore, deodorizing compositions containing antibacterial substances damage the skin's natural flora and occasionally cause intolerances and photosensitivity, or have toxic side effects of varying severity, or exhibit insufficient deodorizing effect. Such compositions are described, among other sources, in: "Diekosmetikn Vorbereitunge" by G.A. Nowak, Volume 2, Verlag für chemische Industrie, H. Ziolkowsky KG, Augsburg 1984, and "Grundlagen und Rezepturen der Kosmetika" by K. Schrader, Dr. Alfred Hüthig Verlag, Heidelberg 1979.

[0004] The object of the present invention was therefore to provide a composition for odor reduction which does not have, or has to a lesser extent, the disadvantages of the disinfecting, deodorizing or odor-masking products available in the prior art.

[0005] This problem is solved by the subject matter of the independent claims. Advantageous embodiments are the subject matter of the dependent claims. The interaction of specific bacterial genera and various application methods results in a previously unattainable benefit. The invention therefore relates to a composition comprising bacteria selected from the group consisting of the genera Lactobacillus spp., Bifidobacterium spp., and Lactococcus spp., as well as the use of this composition and products containing this composition.

[0006] Preferably, the composition according to the invention comprises bacteria selected from the group consisting of Lactobacillus acidophilus, in particular Lactobacillus acidophilus TYCA15, Lactobacillus bifermentans, Lactobacillus alimentarius, Lactobacillus brevis, Lactobacillus crispatus, Lactobacillus iners, Lactobacillus gasseri, Lactobacillus jensenii, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus oryzae, Lactobacillus delbrueckii subsp. delbrueckii, Lactobacillus panis, Lactobacillus delbrueckii subsp.lactis, Lactobacillus paracasei, Lactobacillus helveticus, Lactobacillus parabuchneri, Lactobacillus plantarum, Lactobacillus paraalimentarius, Lactobacillus salivarius, Lactobacillus rhamnosus, Bifidobacterium adolescentis, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactococcus chungangensis, Lactococcus fujiensis, Lactococcus garvieae, Lactococcus lactis, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. hordeniae, Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. tructae, Lactococcus piscium, Lactococcus plantarum, Lactococcus raffi-nolactis and Lactococcus taiwanensis.Particularly preferably, the composition according to the invention comprises bacteria selected from the group consisting of Lactobacillus acidophilus, in particular Lactobacillus acidophilus TYCA15, Lactobacillus bifermentans, Lactobacillus alimentarius, Lactobacillus brevis, Lactobacillus crispatus, Lactobacillus iners, Lactobacillus gasseri, Lactobacillus jensenii, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus panis, Lactobacillus delbrueckii subsp. lactis, Lactobacillus paracasei, Lactobacillus helveticus, Lactobacillus parabuchneri, Lactobacillus plantarum, Lactobacillus salivarius, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Lactococcus garvieae, Lactococcus lactis, Lactococcus piscium, Lactococcus plantarum and Lactococcus raffinolactis.

[0007] In a particular embodiment, the composition according to the invention comprises at least two genera of bacteria, preferably three or four genera of bacteria. In another preferred embodiment, the composition according to the invention comprises at least two, preferably at least three, more preferably at least four, also more preferably at least five, particularly preferably at least six, also particularly preferably at least seven species and / or subspecies of bacteria. In an advantageous embodiment, the composition according to the invention comprises a maximum of 20, preferably a maximum of 15 or twelve, more preferably a maximum of eight species and / or subspecies of bacteria.

[0008] In a preferred embodiment, the composition according to the invention comprises bacteria selected from the group consisting of Lactobacillus acidophilus, in particular Lactobacillus acidophilus TYCA15, Lactobacillus crispatus, Lactobacillus iners, Lactobacillus gasseri, Lactobacillus jensenii, Lactobacillus salivarius, Bifidobacterium animalis, Bifidobacterium adolescentis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium bifidum and Bifidobacterium longum, in particular selected from the group consisting of Lactobacillus acidophilus, in particular Lactobacillus acidophilus TYCA15, Lactobacillus crispatus, Lactobacillus iners, Lactobacillus gasseri, Lactobacillus jensenii, Bifidobacterium adolescentis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium bifidum and Bifidobacterium longum.The composition according to the invention particularly preferably comprises at least the bacteria Lactobacillus acidophilus, in particular Lactobacillus acidophilus TYCA15, Lactobacillus salivarius, Bifidobacterium animalis, Bifidobacterium bifidum and Bifidobacterium longum.

[0009] In a particular embodiment, the composition according to the invention comprises the bacteria Lactobacillus acidophilus TYCA15, Lactobacillus salivarius sp., Bifidobacterium animalis, Bifidobacterium bifidum and Bifidobacterium longum.

[0010] The composition according to the invention is suitable for reducing odor. Furthermore, the composition according to the invention can prevent skin dehydration and / or reduce itching. Using the composition according to the invention can lead to a hormone-induced positive change in the vaginal flora and / or body's appendages; diseases such as urinary tract infections or incontinence become less likely.

[0011] "Pathogenic bacteria" within the meaning of the present invention are bacteria that can cause disease in a mammal, preferably in humans. "Human-pathogenic bacteria" within the meaning of the present invention are bacteria that can cause disease in humans. "Non-pathogenic" bacteria within the meaning of the present invention are bacteria that do not cause disease in a mammal, preferably in humans. The composition according to the invention preferably comprises non-human-pathogenic bacteria, and particularly preferably non-pathogenic bacteria.

[0012] In a particular embodiment, the composition according to the invention is odorless, purely biological, and / or hypoallergenic. In a preferred embodiment, the composition according to the invention comprises non-hybridized and / or non-genetically modified bacteria, which preferably occur in and on the human body. In another preferred embodiment, the composition according to the invention comprises hybridized bacteria.

[0013] The pH of the composition, preferably for application on the skin, especially for use in the intimate and underarm areas, is in a particular embodiment acidic, in the range of less than 7, particularly between 3 and 6, and most preferably between 4 and 5. Odor-inducing bacteria are inhibited in their reproduction and activity by the low pH. Additionally, the composition according to the invention may contain suitable buffers to stabilize the pH.

[0014] In a further preferred embodiment, the use of the composition according to the invention leads to a significant reduction of potentially pathogenic germs that would multiply unhindered in a pH-neutral or slightly alkaline skin environment and can contribute to the occurrence of diseases of the urogenital system.

[0015] In a preferred embodiment, the non-pathogenic bacteria of the composition secrete active substances that inhibit the growth of odor-causing bacteria, particularly pathogenic bacteria. In a particularly preferred embodiment, the composition according to the invention is suitable, when used, for displacing or inactivating odor-causing bacteria located on the skin, especially human pathogenic bacteria, thus inhibiting or preventing the reproduction and activity of the odor-causing bacteria. This reduces odor formation and, furthermore, combats symptoms and diseases such as tissue necrosis, wound exudate, putrid wounds, ozena, hyperhidrosis, osmidrosis, chronic urinary tract infections, chlamydial infections, and halitosis.

[0016] In a preferred embodiment, the composition according to the invention comprises bacteria that inhibit the enzymatic activity of odor-inducing bacteria. Particularly preferably, the composition according to the invention comprises bacteria that lead to competitive inhibition of enzymes with odor-intensive products in the odor-inducing bacteria. In a preferred embodiment, the use of the composition according to the invention simultaneously results in a physiological or substantially physiological restoration of a healthy bacterial flora on the skin, combined with a pH shift into the slightly acidic range.

[0017] In the application according to the invention, the enzymatic activity of the odor-inducing bacteria and their metabolism can be reduced, resulting in a reduction of the malodorous substances. Since the bacteria of the composition according to the invention metabolize bodily excretions in a preferred embodiment, the addition of a nutrient medium in a suspension can be omitted. The composition according to the invention particularly preferably comprises bacteria that directly or indirectly inhibit the enzyme urease, which converts urea into ammonia.

[0018] In a particularly preferred embodiment, the use of the composition according to the invention leads to the establishment of a steady state between odor-causing bacteria and the bacteria contained in the composition. Because the bacteria contained in the composition according to the invention multiply more rapidly when a higher substrate supply is available, the odor-reducing effect of the composition according to the invention can be maintained permanently.

[0019] In a further preferred embodiment, the composition according to the invention comprises bacteria that inhibit the metabolism of the odor-inducing bacteria. Particularly preferably, the composition according to the invention comprises bacteria that inhibit the metabolism of Proteus mirabilis, thereby reducing its formation of trimethylamines.

[0020] Furthermore, the composition according to the invention particularly preferably comprises bacteria that inhibit the metabolism of chlamydia, thereby reducing their excretion products.

[0021] According to the invention, odor-inhibiting bacteria are preferably used, which act as a counterweight to the bacterial origin of unpleasant odors. In a preferred embodiment, the composition according to the invention comprises bacteria whose replication is enhanced by an increased supply of odor-inducing substrates of bacterial origin and / or by bodily excretions.

[0022] The use of the composition according to the invention restores the original, odor-neutral physiological skin flora, thereby preventing the development of unpleasant body odors. Furthermore, necessary personal hygiene measures performed due to odor nuisance can be reduced. As a result, a normal skin environment can re-establish itself.

[0023] In a preferred embodiment, the composition is suitable for use in restoring an odor-neutral body flora in the intimate area, the anal area, and / or in skin areas prone to hyperhidrosis, particularly in the armpits. The composition according to the invention reduces odor-inducing, volatile substances and inhibits the enzymatic activity of odor-inducing bacteria by establishing a steady state. The availability of substrate regulates the proliferation of the bacteria contained in the composition according to the invention.

[0024] According to the invention, it is preferred that the composition contains at least 10 5 or 10 6 , preferably at least 10 7 , especially preferably at least 10 8 , in addition preferably at least 10 9 and most preferably at least 10 10The composition contains non-pathogenic bacteria per gram. In an advantageous embodiment, the composition according to the invention comprises at most 10 14 or 10 12 or 10 10 Non-pathogenic bacteria per gram of the composition. In a particular embodiment, the composition according to the invention comprises non-pathogenic bacteria in an amount in the range of 10 6 up to 10 14 preferably 10 7 up to 10 9 non-pathogenic bacteria per gram of the composition.

[0025] The composition according to the invention can further comprise a nutrient solution to maintain the viability of the bacteria contained therein. Preferably, the nutrient solution is based on sugar, preferably selected from the group consisting of fructose, glucose, sucrose, mannose, maltose, and lactose.

[0026] In a preferred embodiment, the composition according to the invention comprises further components selected from the group consisting of phytotherapeutics, chlorophyll and additional bacteria.

[0027] Preferably, the composition according to the invention comprises bacteria as further components selected from the group consisting of the genus Mobiluncus spp. Suitable additional bacteria of the genus Mobiluncus spp. include species and subspecies selected from the group consisting of Mobiluncus curticei and Mobiluncus mulieris. In a preferred embodiment, the proportion of CFU (colony-forming units) of the additional bacteria, in particular the bacteria of the genus Mobiluncus spp., is 5%, more preferably 3%, and most preferably 1%, based on the total amount of CFU in the composition.

[0028] In a preferred embodiment, the composition, which further contains additional bacteria as components, comprises at least 10 3 , in addition preferably at least 10 4 or 10 5 additional bacteria per gram of the composition. In a further preferred embodiment, the composition, which contains additional bacteria as further components, comprises at most 10 9 , in addition, preferably no more than 10 8 or 10 7 additional bacteria per gram of the composition. In a particular embodiment, the composition according to the invention additionally comprises bacteria, preferably of the genus Mobiluncus spp., in particular bacteria selected from the group consisting of Mobiluncus curticei and Mobiluncus mulieris, in an amount in the range of 10 3 up to 10 7 Bacteria per gram of the composition.

[0029] In a particular embodiment, the composition according to the invention comprises at least one chlorophyll selected from the group consisting of chlorophyll a, chlorophyll b, chlorophyll c1, chlorophyll c2 and chlorophyll d.

[0030] In a particular embodiment, the composition according to the invention has a long shelf life.

[0031] In a preferred embodiment, the composition according to the invention is a cosmetic composition.

[0032] In another preferred embodiment, the composition according to the invention is a medicament that can be used in the treatment of symptoms of tissue necrosis, exuding wounds, pyogenic wounds, and / or putrid wounds. In particular, it is suitable for reducing the odor associated with these symptoms. In another preferred embodiment, the composition according to the invention is a medicament that can be used in the treatment of a disease selected from the group consisting of ozena, hyperhidrosis, osmidrosis, chronic urinary tract infections, chlamydial infections, and halitosis. In particular, it is suitable for reducing the odor associated with these diseases.

[0033] Another aspect of the invention relates to the use of the composition according to the invention for the manufacture of a medicament for therapeutic use in the treatment of symptoms of tissue necrosis, wound secretions or putrid wounds or a disease selected from the group consisting of ozena, hyperhidrosis, osmidrosis, chronic urinary tract infections, chlamydial infections and halitosis.

[0034] Further aspects of the invention relate to a method for treating symptoms of tissue necrosis, wound secretions or putrid wounds, or a disease selected from the group consisting of ozena, hyperhidrosis, osmidrosis, chronic urinary tract infections, chlamydial infections and halitosis, by using the composition according to the invention, as well as the use of the composition according to the invention for treating symptoms of tissue necrosis, wound secretions or putrid wounds, or a disease selected from the group consisting of ozena, hyperhidrosis, osmidrosis, chronic urinary tract infections, chlamydial infections and halitosis.

[0035] The composition according to the invention can be a liquid, a spray, a powder, a paste, a gel, a powder, a suppository, an ointment or a cream, wherein in a particular embodiment the composition according to the invention is microencapsulated or lyophilized.

[0036] The composition according to the invention, containing bacteria of the genus Mobiluncus spp., in particular bacteria selected from the group consisting of Mobiluncus curticei and Mobiluncus mulieris, is in a particular embodiment a suppository. In a preferred embodiment, the suppository according to the invention contains bacteria in an amount in the range of 10 1 up to 10 30 CFU (colony-forming units), especially in the range of 10 2 up to 10 20 KFU, preferably in the range of 10 5 up to 10 18 KBE, preferably in the range of 10 10 up to 10 15 CFU, related to the suppository.

[0037] The composition according to the invention can be used in a two-component, double-container system for liquid and lyophilized components. Furthermore, the composition according to the invention can be incorporated into a membrane or into textiles. It can be used as a liquid, spray, powder, paste, gel, suppository, ointment, or cream. The composition according to the invention can be used for impregnating fibers for personal care products, hygiene products, sanitary products, dressings, and textiles. In particular, the composition according to the invention can be used in diapers, pads, panty liners, tampons, and / or disposable underwear. In addition, the composition according to the invention can be used as an additive in personal care products, as a scented varnish, as a deodorant, as a conditioning foam, and as a dry shampoo.

[0038] In a preferred embodiment, the composition is applied to hygiene products, sanitary ware, and / or textiles that may come into contact with urine. Suitable hygiene products include those for medical, care, and personal use, such as tampons, sanitary napkins, and panty liners. Suitable sanitary ware includes diapers, pads, adult diapers, and disposable underwear. Suitable textiles include underwear, bed linen, nightwear, mattresses, washcloths, and towels.

[0039] In a further preferred embodiment, the composition is applied to dressing material used to cover tissue necrosis, wounds, in particular exuding wounds, pyogenic wounds and / or putrid wounds.

[0040] The invention further relates to a product containing the composition according to the invention, wherein the product is selected from the group consisting of liquids, sprays, powders, pastes, gels, powders, suppositories, ointments, creams, scented varnishes, care articles such as deodorants, care foams, dry shampoos, hygiene articles, sanitary articles, dressings and / or textiles.

[0041] In a preferred embodiment, the product containing the composition according to the invention is selected from the group consisting of hygiene articles, sanitary articles, dressings and / or textiles. Further preferred is the composition according to the invention, which in a particular embodiment is microencapsulated, incorporated into at least one membrane and / or into textiles of the product, and / or fibers of the product are impregnated with the composition according to the invention.

[0042] Suitable hygiene products include those for medical, care, and personal use, such as tampons, sanitary napkins, and panty liners. Suitable sanitary products include diapers, pads, adult diapers, and disposable underwear. Suitable dressings include wound dressings, active wound dressings, wound films, and plasters. Suitable textiles include underwear, bed linen, nightwear, mattresses, washcloths, and towels.

[0043] In a particular embodiment, the dressing material according to the invention is used in the treatment of symptoms of tissue necrosis, exuding wounds, pyogenic wounds and / or putrid wounds.

[0044] Preferably, the product according to the invention contains bacteria in an amount in the range of 10 1 up to 10 30 KBE, especially in the range of 10 2 up to 10 20 KFU, preferably in the range of 10 5 up to 10 18KBE, preferably in the range of 10 10 up to 10 15 CFU, related to the product. Examples: Example 1:1. Experiment description

[0045] Example 1 is a blind study on the in vitro effect of the composition comprising bacteria according to the invention on reducing urine odor. Various samples were tested with and without the composition according to the invention with regard to odor development. 2. Experimental Part 2.1 Experimental Setup

[0046] To create the most realistic conditions possible, an incubator was heated to a stationary temperature of 33°C, which corresponds to the body surface temperature of an average person in the genital area.

[0047] Twelve sterile glass containers were used. The experiment was conducted under sterile conditions. All containers were numbered in such a way as to prevent the evaluators from identifying which container was which during the olfactory assessment.

[0048] At the start of the experiment, it was ensured that all components, such as tweezers, gauze pads, pipettes, and glass containers, were sterile. A folded, sterile gauze pad was placed into each glass container using tweezers. The containers were then filled using pipettes. To ensure consistent conditions, a new sterile pipette was used for each sample.

[0049] Each vessel was filled with 5 ml ± 0.1 ml of urine and 0.5 ml ± 0.1 ml of the composition according to the invention. The concentrations of the samples were therefore equivalent.

[0050] The composition used according to the invention for odor reduction contained the non-pathogenic bacteria Lactobacillus acidophilus TYCA15, Lactobacillus salivarius sp., Bifidobacterium animalis, Bifidobacterium bifidum and Bifidobacterium longum in the ratio 1:1:1:1:1, wherein the composition comprised a total of 10 9 bacteria per gram of the composition.

[0051] The four series of experiments are subdivided as follows: Containers 1, 2, 3 Clean midstream urine sample from a healthy subject Containers 4, 5, 6 Clean midstream urine from a healthy subject and Composition according to the invention Containers 7, 8, 9 Infected urine of a subject with chronic urinary tract infection Containers 10, 11, 12 Infected urine of a subject with chronic urinary tract infection and composition according to the invention

[0052] To achieve statistical significance, three samples were prepared simultaneously for each of the four test series mentioned above. Thus, twelve samples were tested across four test series with different samples and the addition or omission of the composition according to the invention.

[0053] After being filled with urine and, if desired, with the composition according to the invention, the glass containers were sealed under aerobic conditions. Sealing the glass containers served to prevent the urine odor of the respective sample from dissipating too strongly over the course of the experiment. 2.2 Experimental Procedure

[0054] For incubation, the prepared samples were placed in the preheated incubator at a constant temperature of 33°C.

[0055] After the samples were prepared, the odor of the samples was evaluated at predetermined times by two independent assessors using an odor control and a scale (see Table 1). At none of the odor controls did the assessors know which urine was in the containers or whether the composition according to the invention had been added. Table 1: Odor scale 1 No smell 2 light scent 3 Medium odor 4 Stronger odor 5 Strong odor 6 Unbearable smell

[0056] The time intervals for odor control were after sampling and after an incubation period of one hour, two hours, 18 hours and 27 hours.

[0057] The assessment by the assessors was documented in writing after each inspection. 3. Experiment evaluation Table 2: Odor tests sample Clean midstream urine Infected urine Inventive composition smell test before incubation after 1 hour after 2 hours after 18 hours after 27 hours 1 × 0 ml 1 2 2 4 5 2 × 0 ml 1 1 1 4 5 3 × 0 ml 1 2 2 5 5 4 × 0,5 ml 1 1 1 1 1 5 × 0,5 ml 1 1 1 2 2 6 × 0,5 ml 1 1 1 2 2 7 × 0 ml 3 3 3 6 6 8 × 0 ml 3 4 4 6 6 9 × 0 ml 3 3 3 6 6 10 × 0,5 ml 3 2 1 1 1 11 × 0,5 ml 3 3 2 1 1 12 × 0,5 ml 3 3 2 1 1

[0058] Samples 1 to 3 without the composition according to the invention ("Clean urine from a healthy subject") developed from "no / slight odor" to "stronger odor" to "strong odor." Samples 7 to 9 without the composition according to the invention ("Infected urine from a subject with a chronic urinary tract infection"), which exhibited a "moderate / stronger odor" before the start of incubation, developed an "unbearable odor." In both sets of samples, it can be seen that, regardless of the initial bacterial colonization of the samples, a massive odor development occurs after a certain period of time.

[0059] In all three samples of the test series "Clean urine from a healthy subject" with the composition according to the invention, which were assessed as "no odor" before the start of incubation, no significantly increased odor development could be detected after all odor checks. The samples remained almost odorless. This suggests that the composition according to the invention is able to prevent the development of unpleasant odors.

[0060] In the test series "Infected urine of a subject with chronic urinary tract infection" using the composition according to the invention, which was already assessed as having a "medium odor" before incubation began, a reduction in odor was observed as early as the first odor check after one hour of incubation. The composition according to the invention thus not only prevents the development of unpleasant odors, even in the presence of bacterial colonization, but also leads to a reduction in odor. Example 2:1. Experiment description

[0061] Example 2 is a blind study on the in vivo effect of the composition comprising bacteria according to the invention for reducing the odor of urine.

[0062] Following detailed in vitro investigations of the composition according to the invention (see Example 1), the composition according to the invention was tested on two healthy volunteers under dermatological supervision. Subsequently, a trial was conducted on five volunteers with urinary incontinence, also under dermatological supervision. 2. Experimental Procedure 2.1 Test on Healthy Subjects

[0063] Under the supervision of a dermatologist, a 24-hour skin test was performed on healthy volunteers. For this purpose, 1 ml of the composition according to the invention from Example 1 was applied to a sterile plaster and left on the skin for 24 hours. 2.1.1 Result

[0064] During and after the test, there were no signs of skin irritation or allergic reactions. 2.2 Testing subjects with urinary incontinence

[0065] Under medical supervision, a four-day trial was conducted with five subjects suffering from urinary incontinence. The aim of the trial was to test the composition according to the invention in everyday use by people who experience an olfactory burden due to their incontinence.

[0066] Only subjects who met the following conditions were used for the experiment: • Bedridden • Incontinence and reliant on diapers • Urine with a strong, unpleasant odor

[0067] One participant was given antibiotics to treat a respiratory infection during the course of the experiment. Four other participants did not receive antibiotics.

[0068] Using a standard spray bottle with an atomizer (1.8 ml / spray), 9 ml of the composition according to the invention from Example 1 were applied to fresh, untreated incontinence diapers. These were then correctly applied to all five subjects. The diapers were changed as needed during the trial, with 9 ml of the composition according to the invention always being applied to the fresh diapers before application. The diaper change interval ranged from 8 to 24 hours.

[0069] The perceived odors in the room and those of the diapers were documented. A differentiated olfactory evaluation according to Table 1, as in Example 1, was not carried out. 2.2.1 Result

[0070] Table 3: Reduction of the odor of urine and its degradation products during the four-day trial using the composition according to the invention test subject No antibiotics Taking antibiotics Reduction of the odor of urine and its breakdown products diaper Room 1 × Yes Yes 2 × Yes Yes 3 × Yes Yes 4 × Yes Yes 5 × no no

[0071] The following results were obtained following the four-day trial.

[0072] In four of the five incontinent subjects, a significant reduction in urine odor was observed both in the diapers and in the rooms.

[0073] In the test subject who received antibiotics during the four-day trial period, there was no change in odor emission. As expected, the effect of the composition according to the invention is reduced in combination with disinfectant skin care products and / or antibiotic therapy.

[0074] In all four cases, where no antibiotic was administered and no disinfecting skin care products were used, a clear odor neutralization of the urine of the tested subjects occurred both in the diapers and in the rooms.

[0075] None of the participants experienced any adverse side effects during the four-day trial. No allergic reactions, skin irritations, or similar issues were observed.

Claims

[1] Use of a composition comprising bacteria for odor reduction in the treatment of symptoms of tissue necrosis, wound secretions or putrid wounds or of a disease selected from the group consisting of ozena, hyperhidrosis, osmidrosis, chronic urinary tract infections, chlamydial infections and halitosis; wherein the composition comprises the bacteria Lactobacillus acidophilus TYCA15, Lactobacillus salivarius, Bifidobacterium animalis, Bifidobacterium bifidum and Bifidobacterium longum in the ratio 1:1:1:1:1; and the composition totals 10 9 bacteria per gram of the composition. [2] Use for odor reduction according to claim 1, wherein the composition is a liquid, a spray, a powder, a paste, a gel, a powder, a suppository, an ointment or a cream, wherein the composition is preferably microencapsulated or lyophilized. [3] Use for odor reduction according to claim 1 or 2, wherein the composition is incorporated into a membrane or into textiles or is used as an additive in care products, as a scented varnish, as a deodorant, for impregnating fibers for care products, as a care foam or as a dry shampoo, or is applied to hygiene products, sanitary products, dressings and / or textiles. [4] Product for reducing odor in the treatment of symptoms of tissue necrosis, wound secretions or putrid wounds or a disease selected from the group consisting of ozena, hyperhidrosis, osmidrosis, chronic urinary tract infections, chlamydial infections and halitosis; the product contains a composition comprising bacteria; wherein the product is selected from the group consisting of liquids, sprays, powders, pastes, gels, powders, suppositories, ointments, creams, scented varnishes, care products such as deodorants, care foams, dry shampoos, hygiene products, sanitary products, dressings and / or textiles; wherein the composition comprises the bacteria Lactobacillus acidophilus TYCA15, Lactobacillus salivarius, Bifidobacterium animalis, Bifidobacterium bifidum and Bifidobacterium longum in the ratio 1:1:1:1:1; and the composition totals 10 9 bacteria per gram of the composition.